Unique ID issued by UMIN | UMIN000028826 |
---|---|
Receipt number | R000032990 |
Scientific Title | Examination of an influence of inulin intake on functions of the intestines. |
Date of disclosure of the study information | 2017/09/20 |
Last modified on | 2018/03/01 08:34:35 |
Examination of an influence of inulin intake on functions of the intestines.
Examination of an influence of inulin intake on functions of the intestines.
Examination of an influence of inulin intake on functions of the intestines.
Examination of an influence of inulin intake on functions of the intestines.
Japan |
Subjects with a tendency of constipation.
Adult |
Others
NO
To examine the effect of a test food product on bowel habits by selecting males and females with a tendency of constipation as subjects and assigning them to take the test food product on a continuous basis.
Safety,Efficacy
Confirmatory
Explanatory
Intestinal flora
A survey on stool properties
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Prevention
Food |
Intake of the placebo for a week.
Four-week intake of the test food product.
Wash out.
Intake of the placebo for a week.
Four-week intake of the placebo.
Intake of the placebo for a week.
Four-week intake of the placeb.
Wash out.
Intake of the placebo for a week.
Four-week intake of the test food product.
20 | years-old | <= |
59 | years-old | > |
Male and Female
1.Subjects giving written informed consent.
2.Age: Males and females with Japanese nationality aged 20 and over, below 60.
3.Stool frequency: 4 times/week or less.
1.Regular intake of lactobacillus beverage or yogurt (at least once a week)
Persons who can refrain from the intake of yogurt during the study will not be excluded.
2.Currently in treatment with medication or in kinesiotherapy or diet therapy under direction of a doctor.
3.Presence of cardiovascular, hepatic, or renal disorder.
4.Participation in another clinical trial on humans within the last three months or current participation in another clinical trial on humans.
5.Previous history of hepatic disorder or severe disorder related to kidney, endocrine, cardiovascular system, gastro-intestine, lung, blood, or metabolism, or currently presence of complications.
6.Pregnant or nursing, or desired to become pregnant during the study (females only).
7.Irregular work hours such as working on night shift.
8.Presence or previous history of mental disorder (depression, etc.)
9.Currently in treatment or previous history of drug dependence or drug abuse.
10.Current intake of a health food product or supplements with a possible effect on functions of the intestines.
11.Determined by the investigator to be unsuitable for enrollment in this study.
30
1st name | |
Middle name | |
Last name | Toya Hidemasa |
HUMA R&D CORP
Clinical Development Division
Oekkusu Bldg10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
81-3-3431-1260
ochitani@huma-c.co.jp
1st name | |
Middle name | |
Last name | Ochitani Daisuke |
HUMA R&D CORP
Clinical Development Division
Oekkusu Bldg10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
81-3-3431-1260
ochitani@huma-c.co.jp
HUMA R&D CORP
Fuji Nihon Seito Corporation
Profit organization
NO
2017 | Year | 09 | Month | 20 | Day |
Unpublished
Completed
2017 | Year | 07 | Month | 14 | Day |
2017 | Year | 08 | Month | 18 | Day |
2017 | Year | 08 | Month | 25 | Day |
2018 | Year | 03 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032990